Minneman K P, Theroux T L, Hollinger S, Han C, Esbenshade T A
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322.
Mol Pharmacol. 1994 Nov;46(5):929-36.
The potencies and intrinsic activities of agonists in activating cloned alpha 1-adrenergic receptor (AR) subtypes were compared. The hamster alpha 1B-, bovine alpha 1C-, or rat alpha 1A/D-ARs were expressed at high levels in human embryonic kidney 293 cells. Catecholamines and phenylethylamines, but not lower efficacy agonists, were more potent in inhibiting radioligand binding to the expressed alpha 1A/D subtype than to the alpha 1B or alpha 1C subtypes; this selectivity remained in the presence of different buffers, nucleotides, and cations. Activation of all three subtypes caused substantial increases in [3H]inositol phosphate formation in cells grown in 96-well plates. Pretreatment with phenoxybenzamine decreased maximal responses to norepinephrine (NE) with only small decreases in apparent potency, suggesting similar small receptor reserves for all three subtypes. The catecholamines NE, epinephrine, and 6-fluoro-NE were full agonists with similar potencies at the three subtypes; alpha-methyl-NE was also a full agonist but was about 20-fold less potent at alpha 1B-ARs than at alpha 1C- or alpha 1A/D-ARs. Phenylephrine had similar potencies at all three subtypes but gave a submaximal response at alpha 1B-ARs. Methoxamine was a full agonist at alpha 1C- and alpha 1A/D-ARs, with about 20-fold greater potency at the alpha 1C subtype, but showed lower intrinsic activity at alpha 1B-ARs. A number of imidazolines, amidephrine, and SKF 89748 had substantial intrinsic activity at alpha 1C-ARs but little or no intrinsic activity at the other two subtypes. We conclude that the potencies of many agonists in competing for radioligand binding sites are related to their potencies in activating functional responses but that this relationship is not the same for all subtypes. NE and epinephrine activate all three cloned alpha 1-AR subtypes with similar potencies and intrinsic activities, but many widely used agonists show significant selectivity for different alpha 1-AR subtypes.
比较了激动剂激活克隆的α1-肾上腺素能受体(AR)亚型的效能和内在活性。仓鼠α1B-、牛α1C-或大鼠α1A/D-ARs在人胚肾293细胞中高水平表达。儿茶酚胺和苯乙胺,而非效能较低的激动剂,在抑制放射性配体与表达的α1A/D亚型结合方面比与α1B或α1C亚型结合时更有效;在存在不同缓冲液、核苷酸和阳离子的情况下,这种选择性仍然存在。激活所有三种亚型均导致在96孔板中生长的细胞中[3H]肌醇磷酸形成大幅增加。用酚苄明预处理可降低对去甲肾上腺素(NE)的最大反应,而表观效能仅有小幅降低,这表明所有三种亚型的受体储备相似。儿茶酚胺NE、肾上腺素和6-氟-NE是三种亚型的完全激动剂,效能相似;α-甲基-NE也是完全激动剂,但在α1B-ARs上的效能比在α1C-或α1A/D-ARs上低约20倍。去氧肾上腺素在所有三种亚型上的效能相似,但在α1B-ARs上产生次最大反应。甲氧明是α1C-和α1A/D-ARs的完全激动剂,在α1C亚型上的效能约高20倍,但在α1B-ARs上显示出较低的内在活性。一些咪唑啉、酰胺福林和SKF 89748在α1C-ARs上具有显著的内在活性,但在其他两种亚型上几乎没有或没有内在活性。我们得出结论,许多激动剂竞争放射性配体结合位点的效能与其激活功能反应的效能相关,但这种关系并非对所有亚型都相同。NE和肾上腺素以相似的效能和内在活性激活所有三种克隆的α1-AR亚型,但许多广泛使用的激动剂对不同的α1-AR亚型表现出显著的选择性。